A 55-year-old man presents to the clinic with multiple tense bullae diffusely involving his trunk and extremities that overlie urticarial plaques. The patient states that for the past 4 weeks, his ...

Why has a 6-year-old boy with no previous health problems suddenly developed swollen eyelids and reddened patches of skin along with vesicles and erosions on his face, trunk, and limbs, and also ...

Vital Signs: Tympanic temperature 98.9° F (37.2° C), pulse 129, respiratory rate 20/min, blood pressure 121/71 mm Hg, weight 13.9 kg (38%), height 96 cm (50%), peripheral oxygen saturation/room air 99 ...

Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

The two classic forms of impetigo are bullous and nonbullous. Bullous impetigo is sometimes considered a localized form of SSSS. Although found in groups of all ages, impetigo is most commonly seen in ...

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . Researchers identified three different clusters of bullous pemphigoid, the most common autoimmune blistering ...

Bullous myringitis is a type of ear infection in which small, fluid-filled blisters form on the eardrum. These blisters usually cause severe pain. With treatment, bullous myringitis can go away within ...

Please provide your email address to receive an email when new articles are posted on . A 7-year-old girl presented to the ED with a 1-day history of a rash. The patient’s mother first noticed a spot ...

We carried out a thorough and complete review of the husbandry and management practices in cooperation with the floor supervisor and animal caretakers and ruled out chemical, physical, solar and ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...